Who Is At Risk?
Prescription opioids are effective at managing pain, but come with a risk of addiction. It’s important that patients and their physicians understand the risk of addiction before opioids are ever prescribed. AvertD™ can provide the information needed to make a more informed decision when use of prescription opioids is being considered.
Who Is At Risk?
Prescription opioids are effective at managing pain, but come with a risk of addiction. It’s important that patients and their physicians understand the risk of addiction before opioids are ever prescribed. AvertD can provide the information needed to make a more informed decision when use of prescription opioids is being considered.
Designed for Decisions
When making prescribing decisions, AvertD offers an objective method of identifying which patients may be at increased risk of developing opioid addiction—so patients and their providers can tailor pain management plans accordingly. AvertD analyzes 15 genetic markers involved in the brain reward pathways associated with addiction to identify if a patient is at high or low risk.
AvertD requires only a simple cheek swab sample, which is then mailed to our CLIA-certified, CAP-accredited lab for analysis. Results are available to healthcare providers via a secure online portal after the sample is received and processed at the lab.
Know Now, Not Later
AvertD is a prescription, qualitative genotyping test used to identify risk for Opioid Use Disorder (OUD). AvertD test results may provide patients and healthcare providers with additional objective information to support informed decision-making prior to the first prescription of oral opioids for 4-30 days.
Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in a pain management plan.
AvertD was clinically validated through a blinded, multi-center, longitudinal study evaluating patients after their initial exposure to prescription oral opioids for 4 to 30 days (n=385). They were evaluated at least one year post-exposure. The study design allowed for random representative sampling mirroring adults in the U.S. prescribed oral opioids.
In the study, AvertD demonstrated 82% sensitivity and 80% specificity with no statistically significant differences in clinical performance observed based on gender, age, length of follow-up from opioid exposure, race, or ethnicity. In addition, patients with a High Genetic Risk were shown to be 16x more likely to develop OUD than patients with a Low Genetic Risk.* This study demonstrated that AvertD may provide additional objective information regarding a patient’s risk of developing OUD. This information may enable patients and healthcare providers to make more informed decisions when considering the use of oral prescription opioids for between 4 and 30 days.
*Based on an OUD prevalence of 5% in the post-surgical population
Source: Donaldson K, Cardamone D, Genovese M, Garbely J, Demers L. Clinical Performance of a Gene-Based Machine Learning Classifier in Assessing Risk of Developing OUD in Subjects Taking Oral Opioids: A Prospective Observational Study. Ann Clin Lab Sci July-August 2021 vol. 51 no. 4 451-460
#KnowYourRisk for Opioid Addiction
In 2020, more than 93,000 people died from drug overdoses—the highest number of overdose deaths ever recorded. Almost 75% of these deaths were opioid-related. While there are many entry points for opioid misuse and addiction, prescription opioids continue to play a significant role. Although everyone who takes prescription opioids is at risk for addiction, that risk is higher for some people than others, which is why it’s important to #KnowYourRisk.